Abstract 1309
Background
Organized cervical cancer screening program for women aged 30 or over using Pap Smear has been launched in Korea since 1999. However, there is limited evidence showing the effectiveness of this nationwide screening program in reducing cervical cancer mortality. In this study, we aim to examine cervical cancer mortality among screened and non-screened women who participated in the Korean National Cancer Screening Program (KNCSP) from 2002 to 2003.
Methods
We conducted a prospective cohort study of women aged 30-79 years invited to the KNCSP between 2002 - 2003 and followed up to 2015 for deaths from cervical cancer and other causes. Women with incomplete ID, diagnosed with cervical cancer before entering the cohort, or older than 79 years were excluded. Finally, a total of 8,262,267 women aged 30-79 were included, and their cervical cancer screening exposure, cancer incidence, and death information were collected from the KNCSP database, National Cancer Registry, and death certificate from Statistics Korea. There were 6,615,614 women in the screen group (mean person-year: 9.74) and 5,814,989 women in the non-screen group (mean person-year: 8.33). Incidence rate ratio (IRR) and Mortality rate ratio (MRR) were used to compare between screen and non-screen cohorts using Poisson regression model. The MRRs and IRRs were adjusted for age at inclusion in the cohort, insurance type, and self-selection bias.
Results
The crude mortality rate was 3.49 and 8.77 per 100,000 women-years for screen and non-screen group, respectively. MRR for cervical cancer was 0.46 (95% confidence interval (CI): 0.44-0.48). After adjusting for self-selection bias, it was estimated that there was 36.11% of mortality reduction in screen group compared to non-screen group. Also, IRR of invasive cancer in screen group was 0.74 (95% CI: 0.72-0.76) compared to non-screen group. However, there was no significant reduction in the total number of invasive cervical cancer and cervical cancer in situ incidence rate (IRR: 0.98; 95%CI: 0.98 (0.96-1.00)).
Conclusions
We found that after 13 years of follow-up, 36.11% of cervical cancer mortality reduction was observed among women who attended the Korean National Cervical Cancer Screening Program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kui Son Choi.
Funding
National Cancer Center, Korea (Grant number: 1610401) and International Cooperation & Education Program (NCCRI·NCCI 52210-52211,2019) of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3516 - Palbociclib Rechallenge in Hormone Receptor (HR)[+]/HER2[-] Advanced Breast Cancer (ABC). PALMIRA Trial
Presenter: Antonio Llombart Cussac
Session: Poster Display session 2
Resources:
Abstract
4616 - Alpelisib (ALP) + Endocrine Therapy (ET) by Last Prior Therapy in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+) Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC): Additional Study Cohort in BYLieve
Presenter: Eva Ciruelos
Session: Poster Display session 2
Resources:
Abstract
3592 - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Presenter: Tom Degenhardt
Session: Poster Display session 2
Resources:
Abstract
4168 - Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
Presenter: Ning Li
Session: Poster Display session 2
Resources:
Abstract
2785 - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment
Presenter: Jonathan Ledermann
Session: Poster Display session 2
Resources:
Abstract
3496 - Integrated safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
Presenter: Rebecca Kristeleit
Session: Poster Display session 2
Resources:
Abstract
2844 - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Presenter: S.Intidhar Labidi-Galy
Session: Poster Display session 2
Resources:
Abstract
1955 - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study
Presenter: Xiaohua Wu
Session: Poster Display session 2
Resources:
Abstract
2539 - Evaluation of Niraparib 200 mg/d as Maintenance Therapy in Recurrent Ovarian Cancer and Associated Thrombocytopenia in a Real-World US Setting
Presenter: Premal Thaker
Session: Poster Display session 2
Resources:
Abstract
1290 - Niraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer.
Presenter: Jacek Grabowski
Session: Poster Display session 2
Resources:
Abstract